Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework

American Journal of Bioethics

Volumn 15, Issue 12, 2015, Pages 25-29

  Evitt, Niklaus H ^a   Mascharak, Shamik ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

clinical ethics; CRISPR Cas; gene editing; gene therapy; genetic disease; germline modification

Indexed keywords

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; ETHICS; GENETIC DISEASES, INBORN; GENETIC ENGINEERING; GENETICS; GERMLINE MUTATION; HUMAN; LEGISLATION AND JURISPRUDENCE; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; PROCEDURES; PUBLIC POLICY; TRENDS; UNITED STATES;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC DISEASES, INBORN; GENETIC ENGINEERING; GENETIC RESEARCH; GERM-LINE MUTATION; GUIDELINES AS TOPIC; HUMANS; PRENATAL DIAGNOSIS; PUBLIC POLICY; UNITED STATES;

EID: 84948978894     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2015.1104160     Document Type: Article

References (19)

1. D.Baltimore,, P.Berg, M.Botchan, D.Carroll, R.A.Charo, G.Church, J.E.Corn, G.Q.Daley, J.A.Doudna, M.Fenner, H.T.Greely, M.Jinek, G.S.Martin, E.Penhoet, J.Puck, S.H.Sternberg, J.S.Weissman, and K.R.Yamamoto. 2015. A prudent path forward for genomic engineering and germline gene modification. Science 348(6230): 36–38.
2. K.S.Bosley,, M.Botchan, A.L.Bredenoord, D.Carroll, R.A.Charo, E.Charpentier, R.Cohen, J.Corn, J.Doudna, G.Feng, H.T.Greely, R.Isasi, W.Ji, J.S.Kim, B.Knoppers, E.Lanphier, J.Li, R.Lovell-Badge, G.S.Martin, J.Moreno, L.Naldini, M.Pera, A.C.Perry, J.C.Venter, F.Zhang, and Q.Zhou. 2015. CRISPR germline engineering—The community speaks. Nature Biotechnology 33(5): 478–86.
3. F.S.Collins, 2015. Statement on NIH funding of research using gene-editing technologies in human embryos. National Institutes of Health, Department of Health and Human Services. Available at: http://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding-research-using-gene-editing-technologies-human-embryos
4. K.M.Esvelt,, A.L.Smidler, F.Catteruccia, and G.M.Church. 2014. Concerning RNA-guided gene drives for the alteration of wild populations. Elife e03401. doi: 10.7554/eLife.03401.
5. Food and Drug Administration. 2006. FDA guidance for industry: Gene therapy clinical trials—Observing subjects for delayed adverse events. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072957.htm
6. P.D.Hsu, E.S.Lander, and F.Zhang. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6): 1262–78.
7. E.S.Lander, 2015. Brave New Genome. New England Journal of Medicine 373: 5–8.
8. E.Lanphier,, F.Urnov, S.E.Haecker, M.Werner, and J.Smolenski. 2015. Don't edit the human germ line. Nature 519(7544): 410–11.
9. H.Ledford, 2015. CRISPR, the disruptor. Nature 522(7554): 20–24.
10. P.Liang,, Y.Xu, X.Zhang, C.Ding, R.Huang, Z.Zhang, J.Lv, X.Xie, Y.Chen, Y.Li, Y.Sun, Y.Bai, Z.Songyang, W.Ma, C.Zhou, and J.Huang. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell 6(5): 363–72.
11. P.Mali,, L.Yang, K.M.Esvelt, J.Aach, M.Guell, J.E.DiCarlo, J.E.Norville, and G.M.Church. 2013. RNA-guided human genome engineering via Cas9. Science 339(6121): 823–86.
12. J.J.Mezhir,, H.Schmidt, B.Yamini, N.N.Senzer, M.C.Posner, D.W.Kufe, and R.R.Weichselbaum. 2005. Chemo-inducible gene therapy. Anticancer Drugs 16(10): 1053–58.
13. R.Munson,, and L.H.Davis. 1992. Germ-line gene therapy and the medical imperative. Kennedy Institute of Ethics Journal 2(2): 137–158.
14. R.Pollack, 2015. Eugenics lurk in the shadow of CRISPR. Science 348(6237): 871.
15. F.A.Ran,, L.Cong, W.X.Yan, D.A.Scott, J.S.Gootenberg, A.J.Kriz, B.Zetsche, O.Shalem, X.Wu, K.S.Makarova, E.V.Koonin, P.A.Sharp, and F.Zhang. 2015. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520(7546): 186–91.
16. F.A.Ran,, P.D.Hsu, J.Wright, V.Agarwala, D.A.Scott, and F.Zhang. 2013. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8(11): 2281–308.
17. P.Webber, 2014. Does CRISPR-Cas open new possibilities for patents or present a moral maze? Nature Biotechnology 32(4): 331–33.
18. Y.Wu,, H.Zhou, X.Fan, Y.Zhang, M.Zhang, Y.Wang, Z.Xie, M.Bai, Q.Yin, D.Liang, W.Tang, J.Liao, C.Zhou, W.Liu, P.Zhu, H.Guo, H.Pan, C.Wu, H.Shi, L.Wu, F.Tang, and J.Li. 2015. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Research 25: 67–79.
19. A.B.Zimmerman, 2009. Do you hear the people sing? Balancing parental authority and a child's right to thrive: The cochlear implant device. Journal of Health and Biomedical Law 5: 309–329.